Delivery Order SPE2DB22D3501-SPE2DB25FXP17
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $51,681.12 to AmerisourceBergen Drug Corp for the supply of Revlimid 10 mg capsules (28-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete procurement action issued under...
- The Defense Logistics Agency awarded a $51,089.97 delivery order to AmerisourceBergen Drug Corp for Revlimid 10 mg capsules (28-count) on September 9, 2025, with performance completion targeted for September 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a $27,425.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Revlimid 2.5 mg capsules (28-count units), with an ultimate completion date of September 29, 2025. This non-set-aside competitive award was issued on September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $12,329.16 delivery order to AmerisourceBergen Drug Corp for 28 capsules of Revlimid 5 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Revlimid 10 mg capsules (28-count package) with a ceiling value of $102,180.00. This firm fixed-price delivery order, which is expected to be completed by September 17, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was...
- The Defense Logistics Agency awarded a $147,872 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Revlimid 10 mg capsules (28-count packages). This firm fixed-price delivery order, with an ultimate completion date of October 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999 through December 2026. The award was made through open competition with no...
- The Defense Logistics Agency awarded a $51,879.46 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Revlimid 5 mg capsules (100-count units). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The award utilizes no set-aside designation, reflecting the contractor's demonstrated capability to compete in open federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Revlimid 15 mg capsules (100-count units) with a ceiling value of $53,251.31. This firm fixed price delivery order, with a completion date of September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively...
- The Defense Logistics Agency has awarded a delivery order valued at $51,879.46 to AmerisourceBergen Drug Corp for the supply of Revlimid 5 mg capsules (100-count units). This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of September 26, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Revlimid 10 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $52,575.49 and an ultimate completion date of September 26, 2025. This is a competitively awarded, non-set-aside delivery order issued to support federal medical procurement needs. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXP17Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $48,095.44 to AmerisourceBergen Drug Corp for the supply of Revlimid 10 mg capsules (28-count packages). This firm fixed-price, competitively awarded delivery order is scheduled for completion by October 20, 2025, with the product being delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement running through December 2026 that enables comprehensive pharmaceutical supply across multiple therapeutic domains for military and federal healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and has demonstrated strong capability in fulfilling DLA requirements through open competition. The company's extensive portfolio with the Defense Logistics Agency includes delivery of brand-name and generic medications, specialty drugs, and medical supplies supporting military healthcare programs. This award for Revlimid, a branded immunomodulatory drug used in cancer treatment, exemplifies the company's role in supplying specialized pharmaceutical products to support the medical needs of the Defense Health Agency and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.1k | 9/28/25 |